A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
Author:
Affiliation:
1. Department of Urology, Chung-Ang University Gwangmyeoung Hospital, Gwangmyeoung, Korea.
2. Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Funder
National Research Foundation of Korea
Publisher
The Korean Urological Association
Subject
Urology
Link
https://icurology.org/pdf/10.4111/icu.20220061
Reference68 articles.
1. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
2. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
3. Current Therapy for Metastatic Urothelial Carcinoma
4. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
5. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma;Journal of Cellular and Molecular Medicine;2024-05
2. Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review;Cancer Biotherapy and Radiopharmaceuticals;2024-05-01
3. Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis;Frontiers in Oncology;2024-03-14
4. The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer;International Journal of Molecular Sciences;2023-12-23
5. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges;MedComm;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3